Medtronic (NYSE:MDT) responded to a study presented this week which highlighted usability concerns with its MiniMed 670G automated insulin pump, writing that the company had “made many enhancements to the system since the study was done which would likely mitigate many of the issues experienced.”
Earlier this week, physicians from Boston Children’s Hospital reported that nearly one-fifth of participants in a real-world study of the MiniMed 670G stopped using the system within months of it being prescribed, citing dissatisfaction with the technical demands of the system.
Medtronic’s MiniMed 670G system is designed to automatically track and adjust a patient’s blood sugar levels by measuring blood glucose every few minutes and automating the dosing of insulin. The automated insulin delivery system first won FDA approval in September 2016.
In response to the BCH study, Medtronic said in an emailed statement that the company has updated the software in the MiniMed 670G’s transmitter that sends sensor data to the insulin pump.
When the system was first launched in 2017, it included a safety feature that prompted a “continuous request for blood glucose entries,” the company noted.
“To improve the patient experience, we created a software enhancement that removes all additional safety check without compromising patient safety. All MiniMed 670G systems shipping today have this enhanced transmitter, and we are replacing the transmitter for anyone experiencing an issue,” Medtronic added.